Helius Medical Technologies, Inc. Reports Second Quarter 2022 Financial Results
Helius Medical Technologies, Inc. (Nasdaq:HSDT) reported Q2 2022 financial results with revenues increasing by 68% to $119K, primarily from PoNS Therapy sales for MS patients. The company initiated U.S. commercial sales and launched a Patient Therapy Access Program to improve accessibility. Operating expenses decreased to $3.5M, leading to a reduced net loss of $3.8M compared to $6.0M in Q2 2021. Cash reserves total $19.7M post-recent financing, expected to fund operations through 2023. The company anticipates modest revenue growth for Q3, driven by continued sales coverage and patient pairing efforts.
- Q2 2022 revenue increased by 68% to $119K.
- Operating expenses decreased to $3.5M from $6.2M year-over-year.
- Net loss reduced to $3.8M from $6.0M year-over-year.
- Proforma cash balance at June 30, 2022, is $19.7M.
- Sequential revenue growth was lower than expected.
- Cash reserves decreased from $11.0M at the end of 2021.
-- Net proceeds from August 2022 financing and cash on hand expected to fund operations through 2023 --
-- Company to host call at 4:30pm today --
NEWTOWN, Pa., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended June 30, 2022.
Second Quarter and Recent Business Updates
- Fulfilled first U.S. prescriptions of PoNS Therapy for use in multiple sclerosis (“MS”) patients experiencing gait deficit.
- Made PoNS Therapy training available online and on-demand in July, eliminating a major bottleneck to patient access.
- Launched Patient Therapy Access Program in June to provide qualifying patients access to on-label PoNS Therapy at a significantly reduced price.
- Added Shepherd Center in Atlanta, Georgia to the Company-sponsored Therapeutic Experience Program (“TEP”), an open label observational interventional trial designed to evaluate the impact of subjects’ adherence on PoNS Therapy outcomes in patients with MS.
- Q2 2022 revenue increased by
68% to$119 thousand compared to$71 thousand in Q2 2021. - Closed an
$18 million public offering on August 9th, raising net proceeds of approximately$16.4 million .
“The second quarter saw the start of PoNS commercial sales in the United States, and we have already received several hundred inquiries. Though revenue during the quarter increased on a year-over-year basis, we did not have the sequential growth we’d expected. As a result, we’ve implemented several programs to eliminate the impediments to prescription fulfillment. First, we introduced an online training module so physical therapists can be trained in three hours or less, at the therapist’s own pace, instead of through an in-person, multi-day course. This module, which became available in mid-July, is already proving effective in onboarding physical therapists and clinics speedily and more efficiently, without added cost, allowing patients and physicians to spend less time waiting for a qualified and available therapist,” said Dane Andreeff, President and Chief Executive Officer of Helius. “On June 1st, we also announced the launch of the Patient Therapy Access Program, which provides patients suffering from MS access to on-label PoNS Therapy at a greatly reduced price and, later this year, we will roll out our online pharmacy initiative. Through a network of fully licensed providers with e-prescribing capabilities, our upcoming direct-to-consumer e-platform will streamline access to PoNS Therapy, and further reduce the time it takes for a patient to get the treatment they need.”
“We are excited to build on this momentum going into the second half of the year, and our recently announced public offering gives us the runway to focus on getting PoNS Therapy to as many patients as possible,” concluded Mr. Andreeff.
Second Quarter 2022 Financial Results
Total revenue for the second quarter of 2022 was
For the three months ended June 30, 2022, cost of sales was
Operating expenses for the second quarter of 2022 decreased to
Operating loss for the second quarter of 2022 decreased
Net loss was
As of June 30, 2022, the Company had cash of
Third Quarter and Near-Term Guidance
The Company currently expects third quarter revenue to be modestly above the second quarter levels, factoring in the timing required to pair patients with trained physical therapists and potential delays for some portion of U.S. patients to pursue insurance coverage prior to filling their prescriptions. As we continue to build momentum and expand our sales coverage, the Company expects future quarterly revenue to continue increasing sequentially quarter over quarter throughout the year and through 2023 as the U.S. commercialization of PoNS develops.
Conference Call
As previously announced, management will host a conference call as follows:
| Date: | Monday, August 15, 2022 |
| Time: | 4:30 PM ET |
| Register* (Audio Only): | Click Here |
| Webcast: | https://edge.media-server.com/mmc/p/uaji4a8t |
The webcast will be archived under the Newsroom section of the Company’s investor relations website.
* Beginning this quarter, conference call participants should register to obtain their dial-in and passcode details. The new, streamlined process improves security and eliminates wait times when joining the call. Please be sure to register using a valid email address.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com.
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator (PoNS) is an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to improve balance and gait. The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. Helius is advancing PoNS post-approval research in MS through a recently launched Therapeutic Experience Program (TEP) designed to partner with neurologists and neurorehabilitation therapists at 10-12 US centers of excellence, who express an interest in becoming “early adopters” of PoNS therapy. For more information visit www.ponstherapy.com.
PoNS is also authorized for sale in Canada for two indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) for use as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.
Cautionary Disclaimer Statement:
This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “continue,” “expect,” “will,” “goal,” “aim to” and similar expressions. Such forward-looking statements include, among others, statements regarding the Company’s future growth and operational progress, including commercial activities for the PoNS device, projected revenue from sales of our products, progress of commercialization of the PoNS device in the U.S., the ability and timing of our customers’ ability to seek reimbursement for the PoNS device in the U.S., expectations for the Therapeutic Experience Program, clinical development plans, and product development activities.
There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties associated with the Company’s capital requirements to achieve its business objectives, availability of funds, the ability to find additional sources of funding, the impact of the COVID-19 pandemic, manufacturing, labor shortage and supply chain risks, the Company’s ability to train physical therapists in the supervision of the use of the PoNS treatment, the Company’s ability to secure contracts with rehabilitation clinics, the Company’s ability to obtain national Medicare coverage and to obtain a reimbursement code so that the PoNS device is covered by Medicare and Medicaid, the Company’s ability to build internal commercial infrastructure, secure state distribution licenses, build a commercial team and build relationships with Key Opinion Leaders, neurology experts and neurorehabilitation centers, market awareness of the PoNS device, future clinical trials and the clinical development process, ongoing government regulation and other factors, and other risks detailed from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.
The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.
Investor Relations Contact:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Helius Medical Technologies, Inc.
Unaudited Condensed Consolidated Statements of Operations
(Amounts in thousands except shares and per share data)
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue: | ||||||||||||||||
| Product sales, net | $ | 119 | $ | 63 | $ | 302 | $ | 140 | ||||||||
| Other revenue | — | 8 | 7 | 15 | ||||||||||||
| Total operating revenue | 119 | 71 | 309 | 155 | ||||||||||||
| Cost of sales: | ||||||||||||||||
| Cost of product sales | 88 | 67 | 212 | 83 | ||||||||||||
| Gross profit | 31 | 4 | 97 | 72 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 953 | 1,377 | 2,717 | 2,694 | ||||||||||||
| Selling, general and administrative | 2,461 | 4,744 | 5,280 | 6,939 | ||||||||||||
| Amortization expense | 47 | 49 | 94 | 106 | ||||||||||||
| Total operating expenses | 3,461 | 6,170 | 8,091 | 9,739 | ||||||||||||
| Operating loss | (3,430 | ) | (6,166 | ) | (7,994 | ) | (9,667 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Other income | — | — | 1 | — | ||||||||||||
| Foreign exchange (loss) gain | (380 | ) | 185 | (163 | ) | 324 | ||||||||||
| Net other income (expense) | (380 | ) | 185 | (162 | ) | 324 | ||||||||||
| Loss before provision for income taxes | (3,810 | ) | (5,981 | ) | (8,156 | ) | (9,343 | ) | ||||||||
| Provision for income taxes | — | — | — | — | ||||||||||||
| Net loss | $ | (3,810 | ) | $ | (5,981 | ) | $ | (8,156 | ) | $ | (9,343 | ) | ||||
| Net loss per share | ||||||||||||||||
| Basic | $ | (0.97 | ) | $ | (2.58 | ) | $ | (2.11 | ) | $ | (4.29 | ) | ||||
| Diluted | $ | (0.97 | ) | $ | (2.58 | ) | $ | (2.11 | ) | $ | (4.29 | ) | ||||
| Weighted average shares outstanding | ||||||||||||||||
| Basic | 3,928,704 | 2,317,389 | 3,858,676 | 2,179,878 | ||||||||||||
| Diluted | 3,928,704 | 2,317,389 | 3,858,676 | 2,179,878 | ||||||||||||
Helius Medical Technologies, Inc.
Unaudited Condensed Consolidated Balance Sheets
(Except for share data, amounts in thousands)
| June 30, 2022 | December 31, 2021 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | 3,273 | $ | 11,005 | ||||
| Accounts receivable, net | 9 | 66 | ||||||
| Other receivables | 187 | 185 | ||||||
| Inventory, net | 577 | 476 | ||||||
| Prepaid expenses | 996 | 862 | ||||||
| Other current assets | 22 | — | ||||||
| Total current assets | 5,064 | 12,594 | ||||||
| Property and equipment, net | 365 | 409 | ||||||
| Other assets | ||||||||
| Goodwill | 753 | 763 | ||||||
| Intangible assets, net | 236 | 333 | ||||||
| Operating lease right-of-use asset, net | 128 | 3 | ||||||
| Total other assets | 1,117 | 1,099 | ||||||
| TOTAL ASSETS | $ | 6,546 | $ | 14,102 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 1,043 | $ | 1,069 | ||||
| Accrued liabilities | 654 | 1,433 | ||||||
| Operating lease liability | 52 | 3 | ||||||
| Deferred revenue | 28 | 148 | ||||||
| Total current liabilities | 1,777 | 2,653 | ||||||
| Non-current liabilities | ||||||||
| Operating lease liability | 83 | — | ||||||
| Deferred revenue | 184 | 193 | ||||||
| TOTAL LIABILITIES | 2,044 | 2,846 | ||||||
| STOCKHOLDERS’ EQUITY | ||||||||
| Preferred stock, | — | — | ||||||
| Class A common stock, | 4 | 4 | ||||||
| Additional paid-in capital | 150,665 | 149,412 | ||||||
| Accumulated deficit | (145,191 | ) | (137,035 | ) | ||||
| Accumulated other comprehensive loss | (976 | ) | (1,125 | ) | ||||
| TOTAL STOCKHOLDERS’ EQUITY | 4,502 | 11,256 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 6,546 | $ | 14,102 | ||||
FAQ
What were HSDT's Q2 2022 financial results?
What is the future revenue outlook for HSDT?
How has HSDT's cash position changed recently?
What initiatives did HSDT launch for PoNS Therapy?
